Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

被引:50
作者
Frumovitz, Michael
Sood, Anil K.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
vascular endothelial growth factor (VEGF); angiogenesis; gynecologic cancer;
D O I
10.1016/j.ygyno.2006.10.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, which is required for tumor growth and metastasis. In this article, a review of the functional and biological roles of the VEGF pathway in driving angiogenesis and growth of gynecologic malignancies was performed. Based on the biological functions of VEGF, multiple approaches for targeting the VEGF/VEGF-receptor complex have been developed and many of these have demonstrated substantial activity in preclinical models. These promising data have led to rapid clinical development of VEGF-targeted agents. Therefore, we also assessed the status of VEGF-targeted therapies and associated toxicities in gynecologic malignancies. However, many questions remain related to optimal dosing, sequencing of therapies, management of toxicities, appropriate patient selection, and assessment of response, which will require further studies. Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:768 / 778
页数:11
相关论文
共 81 条
[51]  
Mendel DB, 2003, CLIN CANCER RES, V9, P327
[52]   Role of vascular endothelial growth factor in ovarian cancer -: Inhibition of ascites formation by immunoneutralization [J].
Mesiano, S ;
Ferrara, N ;
Jaffe, RB .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (04) :1249-1256
[53]   Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer [J].
Monk, Bradley J. ;
Han, Ernest ;
Josephs-Cowan, Carol A. ;
Pugmire, Gordon ;
Burger, Robert A. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :140-144
[54]   The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma [J].
Numnum, T. Michael ;
Rocconi, Rodney P. ;
Whitworth, Jenny ;
Barnes, Mack N. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :425-428
[55]  
Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO
[56]  
2-A
[57]   Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma [J].
Ratain, Mark J. ;
Eisen, Tim ;
Stadler, Walter M. ;
Flaherty, Keith T. ;
Kaye, Stan B. ;
Rosner, Gary L. ;
Gore, Martin ;
Desai, Apurva A. ;
Patnaik, Amita ;
Xiong, Henry Q. ;
Rowinsky, Lric ;
Abbruzzese, James L. ;
Xia, Chenghua ;
Simantov, Ronit ;
Schwartz, Brian ;
O'Dwyer, Peter J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2505-2512
[58]   Mechanisms of angiogenesis [J].
Risau, W .
NATURE, 1997, 386 (6626) :671-674
[59]   Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results [J].
Rugo, HS ;
Herbst, RS ;
Liu, G ;
Park, JW ;
Kies, MS ;
Steinfeldt, HM ;
Pithavala, YK ;
Reich, SD ;
Freddo, JL ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5474-5483
[60]   pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade [J].
Sanseverino, F ;
Santopietro, R ;
Torricelli, M ;
D'Andrilli, G ;
Russo, G ;
Cevenini, G ;
Bovicelli, A ;
Leoncini, L ;
Scambia, G ;
Petraglia, F ;
Claudio, PP ;
Giordano, A .
CANCER BIOLOGY & THERAPY, 2006, 5 (01) :84-88